Joshua A. Kaplan

1.9k citations

25 papers · 1.0k indexed · h-index 19

Co-authors: Arie Zask Ker Yu Lourdes Toral‐Barza Jeroen C. Verheijen Kevin J. Curran Semiramis Ayral‐Kaloustian Irwin Hollander Judy Lucas
Topics: PI3K/AKT/mTOR signaling in cancer (13 papers)Ubiquitin and proteasome pathways (7 papers)Glycosylation and Glycoproteins Research (5 papers)
Cited by: Organic Chemistry Molecular Biology Toxicology
Journals: Journal of the American Chemical Society Nature Communications Biochemistry
Partner nations: United States Canada United Kingdom

In The Last Decade

Joshua A. Kaplan

23 papers receiving 989 citations

Peers

Countries citing papers authored by Joshua A. Kaplan

Since Specialization

Citations

This map shows the geographic impact of Joshua A. Kaplan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua A. Kaplan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua A. Kaplan more than expected).

Fields of papers citing papers by Joshua A. Kaplan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua A. Kaplan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua A. Kaplan. The network helps show where Joshua A. Kaplan may publish in the future.

Co-authorship network of co-authors of Joshua A. Kaplan

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua A. Kaplan. A scholar is included among the top collaborators of Joshua A. Kaplan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua A. Kaplan. Joshua A. Kaplan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Discovery of GS-1291269: A Neutral Ketohexokinase (KHK) Inhibitor with an Unusual Thietane Amine Functional Group 2025 ·Journal of Medicinal Chemistry ·(unknown),(unknown),Ryan Ferrao,Joshua A. Kaplan,(unknown),(unknown),(unknown),Shawn S. Badal,(unknown),(unknown),(unknown),Kirk L. Stevens,J. Logan Bachman,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Petr Jansa	0
2	A structural and dynamic model for the assembly of Replication Protein A on single-stranded DNA 2018 ·Nature Communications ·Luke A. Yates,Ricardo Aramayo,Nilisha Pokhrel,Colleen C. Caldwell,Joshua A. Kaplan,Rajika L. Perera,Maria Spies,Edwin Antony,Xiaodong Zhang	100
3	Discovery of a Phosphoinositide 3-Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856 2017 ·Journal of Medicinal Chemistry ·Stéphane Perreault,Jayaraman Chandrasekhar,Zhi-Hua Cui,Jerry Evarts,Hao Jia,Joshua A. Kaplan,Adam Kashishian,Kathleen S. Keegan,Thomas Kenney,David Koditek,Latesh Lad,Eve‐Irene Lepist,Mary E. McGrath,Leena Patel,Bart Phillips,Joseph Therrien,Jennifer Treiberg,(unknown),Gary B. Phillips	27
4	Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2 2010 ·Cancer Research ·Ker Yu,Celine Shi,Lourdes Toral‐Barza,Judy Lucas,Boris Shor,(unknown),Weiguo Zhang,Robert Mahoney,(unknown),(unknown),(unknown),(unknown),Kevin J. Curran,Joshua A. Kaplan,Jeroen C. Verheijen,Semiramis Ayral‐Kaloustian,Tarek S. Mansour,Robert T. Abraham,Arie Zask,James J. Gibbons	162
5	2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: Optimization of human microsomal stability 2010 ·Bioorganic & Medicinal Chemistry Letters ·Jeroen C. Verheijen,David J. Richard,Kevin J. Curran,Joshua A. Kaplan,Ker Yu,Arie Zask	22
6	Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 1-substituent 2010 ·Bioorganic & Medicinal Chemistry Letters ·Kevin J. Curran,Jeroen C. Verheijen,Joshua A. Kaplan,David J. Richard,Lourdes Toral‐Barza,Irwin Hollander,Judy Lucas,Semiramis Ayral‐Kaloustian,Ker Yu,Arie Zask	61
7	Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors 2010 ·Bioorganic & Medicinal Chemistry Letters ·Arie Zask,Jeroen C. Verheijen,David J. Richard,Joshua A. Kaplan,Kevin J. Curran,Lourdes Toral‐Barza,Judy Lucas,Irwin Hollander,Ker Yu	33
8	Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: Discovery of highly potent and selective analogs with improved human microsomal stability 2009 ·Bioorganic & Medicinal Chemistry Letters ·David J. Richard,Jeroen C. Verheijen,Kevin J. Curran,Joshua A. Kaplan,Lourdes Toral‐Barza,Irwin Hollander,Judy Lucas,Ker Yu,Arie Zask	42
9	Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR) 2009 ·Bioorganic & Medicinal Chemistry Letters ·Joshua A. Kaplan,Jeroen C. Verheijen,Natasja Brooijmans,Lourdes Toral‐Barza,Irwin Hollander,Ker Yu,Arie Zask	41
10	Abstract B145: Highly selective pyrazolopyrimidine mTOR inhibitors with profound in vivo antitumor activity 2009 ·Molecular Cancer Therapeutics ·Arie Zask,Joshua A. Kaplan,Kevin J. Curran,Jeroen C. Verheijen,David J. Richard,Natasja Brooijmans,Eric M. Bennett,Judy Lucas,Lourdes Toral‐Barza,Irwin Hollander,James J. Gibbons,Robert T. Abraham,Semiramis Ayral‐Kaloustian,Tarek S. Mansour,Ker Yu	2
11	Discovery of Potent and Selective Inhibitors of the Mammalian Target of Rapamycin (mTOR) Kinase 2009 ·Journal of Medicinal Chemistry ·Paweł Nowak,Derek C. Cole,Natasja Brooijmans,Matthew G. Bursavich,Kevin J. Curran,John W. Ellingboe,James J. Gibbons,Irwin Hollander,Yongbo Hu,Joshua A. Kaplan,David J. Malwitz,Lourdes Toral‐Barza,Jeroen C. Verheijen,Arie Zask,Weiguo Zhang,Ker Yu	46
12	Morpholine Derivatives Greatly Enhance the Selectivity of Mammalian Target of Rapamycin (mTOR) Inhibitors 2009 ·Journal of Medicinal Chemistry ·Arie Zask,Joshua A. Kaplan,Jeroen C. Verheijen,David J. Richard,Kevin J. Curran,Natasja Brooijmans,Eric M. Bennett,Lourdes Toral‐Barza,Irwin Hollander,Semiramis Ayral‐Kaloustian,Ker Yu	81
13	Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors 2005 ·Bioorganic & Medicinal Chemistry Letters ·Arie Zask,Joshua A. Kaplan,Xuemei Du,(unknown),Vincent Sandanayaka,(unknown),Jeremy I. Levin,Guixian Jin,Jun Xu,Terri Cummons,D. Barone,Semiramis Ayral‐Kaloustian,Jerauld S. Skotnicki	23
14	Hybrids of the Hemiasterlin Analogue Taltobulin and the Dolastatins Are Potent Antimicrotubule Agents 2005 ·Journal of the American Chemical Society ·Arie Zask,Joshua A. Kaplan,Sylvia Musto,Frank Loganzo	22
15	Two Photoaffinity Analogues of the Tripeptide, Hemiasterlin, Exclusively Label α-Tubulin 2005 ·Biochemistry ·Maria Nunes,Joshua A. Kaplan,Joseph L. Wooters,Malathi Hari,Albert A. Minnick,(unknown),Celine Shi,Sylvia Musto,Carl F. Beyer,Girija Krishnamurthy,Yongchang Qiu,Frank Loganzo,Semiramis Ayral‐Kaloustian,Arie Zask,Lee M. Greenberger	22
16	Hemiasterlin analogs exclusively label α-tubulin at the interdimer region and specifically block subtilisin digestion of α-tubulin 2004 ·Cancer Research ·Malathi Hari,Maria Nunes,Arie Zask,Joshua A. Kaplan,Joseph L. Wooters,Albert A. Minnick,(unknown),Sylvia Musto,Carl F. Beyer,Girija Krishnamurthy,Yongchang Qiu,Frank Loganzo,Semiramis Ayral‐Kaloustian,Lee M. Greenberger	1
17	Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin. 2004 ·PubMed ·Frank Loganzo,Malathi Hari,Tami Annable,Xingzhi Tan,(unknown),Sylvia Musto,Arie Zask,Joshua A. Kaplan,Albert A. Minnick,(unknown),Semiramis Ayral‐Kaloustian,Marianne S. Poruchynsky,Tito Fojo,Lee M. Greenberger	25
18	D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitors 2004 ·Bioorganic & Medicinal Chemistry Letters ·Arie Zask,Gary H. Birnberg,(unknown),Joshua A. Kaplan,(unknown),(unknown),Ayako Yamashita,Carl F. Beyer,Girija Krishnamurthy,Lee M. Greenberger,Frank Loganzo,Semiramis Ayral‐Kaloustian	13
19	Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment 2004 ·Bioorganic & Medicinal Chemistry Letters ·Ayako Yamashita,(unknown),Joshua A. Kaplan,(unknown),Frank Loganzo,Richard Hernandez,Carl F. Beyer,Tami Annable,Sylvia Musto,Carolyn Discafani,Arie Zask,Semiramis Ayral‐Kaloustian	16
20	Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in α-tubulin 2004 ·Molecular Cancer Therapeutics ·Frank Loganzo,Malathi Hari,Tami Annable,Xingzhi Tan,(unknown),Sylvia Musto,Arie Zask,Joshua A. Kaplan,Albert A. Minnick,(unknown),Semiramis Ayral‐Kaloustian,Marianne S. Poruchynsky,Tito Fojo,Lee M. Greenberger	24

About Joshua A. Kaplan

Joshua A. Kaplan is a scholar working on Molecular Biology, Organic Chemistry and Cell Biology, having authored 25 papers that have together received 1.0k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (13 papers), Ubiquitin and proteasome pathways (7 papers) and Glycosylation and Glycoproteins Research (5 papers). The work is most often cited by research in Organic Chemistry (413 citations), Molecular Biology (716 citations) and Toxicology (20 citations). Joshua A. Kaplan has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Arie Zask, Ker Yu, Lourdes Toral‐Barza, Jeroen C. Verheijen, Kevin J. Curran, Semiramis Ayral‐Kaloustian, Irwin Hollander, Judy Lucas, David J. Richard and Natasja Brooijmans. Their work appears in journals such as Journal of the American Chemical Society, Nature Communications and Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact